Metabolic and Hormonal Profile of Insulin-Like Peptide 5 (INSL5) in Polycystic Ovary Syndrome: A Prospective Analysis

Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder with diverse metabolic and hormonal manifestations. Insulin-like peptide 5 (INSL5), a gut-derived hormone of the relaxin/insulin family, is expressed in the central nervous system, colonic and reproductive tissues, but its clinical significance in PCOS remains unclear. This study aimed to evaluate circulating INSL5 levels in PCOS and explore their associations with key hormonal and metabolic parameters. In this prospective cross-sectional study, 45 women with newly diagnosed PCOS and 35 age-matched healthy controls (18–35 years) were evaluated. Clinical characteristics, hormonal profiles, and metabolic markers – including serum anti-Müllerian hormone (AMH) and INSL5 – were assessed. INSL5 levels were measured using enzyme-linked immunosorbent assay (ELISA). Median serum INSL5 levels did not differ significantly between PCOS and control groups (12.5 vs. 15.5 ng/ml; p=0.103). However, within the PCOS group, INSL5 was inversely correlated with body mass index, insulin, HOMA-IR, total and LDL cholesterol, triglycerides, fat mass, and free androgen index, and positively correlated with sex hormone-binding globulin (p<0.05 for all). AMH was significantly higher in the PCOS group and demonstrated a diagnostic cut-off of 5.04 ng/ml (AUC: 0.808; sensitivity: 75.6%; specificity: 74.3%). Although INSL5 did not show diagnostic utility for PCOS, its consistent associations with insulin resistance, androgenic activity, and lipid metabolism suggest a potential role in metabolic regulation. These findings support its relevance as a candidate marker for metabolic phenotyping and warrant further investigation into its physiological role within the PCOS spectrum.

Keywords

PCOS - INSL5 - AMH - metabolic parameters - gut hormones

Publication History

Received: 05 May 2025

Accepted after revision: 11 June 2025

Article published online:
01 July 2025

• References

• 1 Bozdag G, Mumusoglu S, Zengin D. et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016; 31: 2841-2855
• 2 Li M, Chang Q, Luo Y. et al. The gut microbial composition in polycystic ovary syndrome with hyperandrogenemia and its association with steroid hormones. Front Cell Dev Biol 2024; 12: 1384233
• 3 Teede HJ, Tay CT, Laven JJ. et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol 2023; 189: G43-G64
• 4 Hajam YA, Rather HA, Kumar R. et al. A review on critical appraisal and pathogenesis of polycystic ovarian syndrome. Endocr Metab Sci 2024; 14: 100162
• 5 Calzada M, López N, Noguera JA. et al. AMH in combination with SHBG for the diagnosis of polycystic ovary syndrome. J Obstetr Gynaecol 2019; 39: 1130-1136
• 6 Iliodromiti S, Kelsey TW, Anderson RA. et al. Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013; 98: 3332-3340
• 7 Dewailly D, Gronier H, Poncelet E. et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011; 26: 3123-3129
• 8 Vale-Fernandes E, Pignatelli D, Monteiro MP. Should anti-Müllerian hormone be a diagnosis criterion for polycystic ovary syndrome? An in-depth review of pros and cons. Eur J Endocrinol. 2025 192. R29-R43
• 9 Wu H, Handley TN, Hoare BL. et al. Developing insulin-like peptide 5-based antagonists for the G protein-coupled receptor, RXFP4. Biochem Pharmacol 2024; 224: 116239
• 10 Conklin D, Lofton-Day CE, Haldeman BA. et al. Identification of INSL5, a new member of the insulin superfamily. Genomics 1999; 60: 50-56
• 11 Burnicka-Turek O, Mohamed BA, Shirneshan K. et al. INSL5-deficient mice display an alteration in glucose homeostasis and an impaired fertility. Endocrinology 2012; 153: 4655-4665
• 12 Bicer M, Alan M, Alarslan P. et al. Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome. J Endocrinol Invest 2019; 42: 303-312
• 13 Chen Y, Deng M, Chen Z. et al. Insulin-like peptide 5 (INSL5) positively correlates with anti-Müllerian hormone (AMH) in women with the polycystic ovary syndrome: a case-control study. J Ovarian Res 2022; 15: 118
• 14 Group A-SPCW. Eshre TR. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
• 15 Luo X, Li T, Zhu Y. et al. The insulinotrophic effect of insulin-like peptide 5 in vitro and in vivo. Biochem J 2015; 466: 467-473
• 16 Lee YS, De Vadder F, Tremaroli V. et al. Insulin-like peptide 5 is a microbially regulated peptide that promotes hepatic glucose production. Mol Metab 2016; 5: 263-270
• 17 Billing LJ, Smith CA, Larraufie P. et al. Co-storage and release of insulin-like peptide-5, glucagon-like peptide-1 and peptideYY from murine and human colonic enteroendocrine cells. Mol Metab 2018; 16: 65-75
• 18 Grosse J, Heffron H, Burling K. et al. Insulin-like peptide 5 is an orexigenic gastrointestinal hormone. Proc Natl Acad Sci USA 2014; 111: 11133-11138
• 19 Ang SY, Evans BA, Poole DP. et al. INSL5 activates multiple signalling pathways and regulates GLP-1 secretion in NCI-H716 cells. J Mol Endocrinol 2018; 60: 213-224
• 20 Ang SY, Hutchinson DS, Patil N. et al. Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor. Br J Pharmacol 2017; 174: 1077-1089
• 21 Zaykov AN, Gelfanov VM, Perez-Tilve D. et al Insulin-like peptide 5 fails to improve metabolism or body weight in obese mice. Peptides 2019; 120: 170116
• 22 Hechter D, Vahkal B, Tiede T. et al. Reviewing the physiological roles of the novel hormone-receptor pair INSL5-RXFP4: a protective energy sensor?. J Mol Endocrinol 2022; 69: R45-R62
• 23 Di Vincenzo A, Crescenzi M, Granzotto M. et al. Body weight reduction by bariatric surgery reduces the plasma levels of the novel orexigenic gut hormone insulin-like peptide 5 in patients with severe obesity. J Clin Med 2023; 12: 3752
• 24 Wagner I, Flehmig G, Scheuermann K. et al. Insulin-like peptide 5 interacts with sex hormones and metabolic parameters in a gender and adiposity dependent manner in humans. Horm Metab Res 2016; 48: 589-594
• 25 Chen Y, Chen J, Li Y. et al. Insulin-like peptide 5 is associated with insulin resistance in women with polycystic ovary syndrome. J Diabetes Complicat 2023; 37: 108493
• 26 Ivell R, Anand-Ivell R. Insulin-like peptide 3 (INSL3) is a major regulator of female reproductive physiology. Hum Reprod Update 2018; 24: 639-651
• 27 Pelusi C, Fanelli F, Pariali M. et al. Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. J Clin Endocrinol Metab 2013; 98: E1575-E1582
• 28 Seyam E, Hefzy E. Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent. Gynecol Endocrinol 2018; 34: 481-488
• 29 Spanel-Borowski K, Schäfer I, Zimmermann S. et al. Increase in final stages of follicular atresia and premature decay of corpora lutea in Insl3-deficient mice. Mol Reprod Dev 2001; 58: 281-286